1-9 of 9
Xuejun Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exposure-Response Relationships for Axatilimab, a Humanized Monoclonal Antibody Targeting CSF-1R, in Patients with Chronic Graft-Versus-Host Disease

Yan-ou Yang, Alina Volkova, Victor Sokolov, Xing Liu, Cristina Leon, Yuri Kosinsky, Jennifer Sheng, Xuejun Chen
Journal: Blood
Blood (2024) 144 (Supplement 1): 2140.
https://doi.org/10.1182/blood-2024-194594
Published: 2024
Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Justin M. Watts, Anthony M. Hunter, Alessandro Vannuchhi, Vikas Gupta, Srinivas K Tantravahi, Alessandra Iurlo, Brandon McMahon, Francesca Palandri, María Teresa Gómez Casares, Junichiro Yuda, Emma Searle, Anna B. Halpern, Rosa Ayala, Akihiro Tomita, Blanca Xicoy, Prithviraj Bose, Brandi N. Reeves, Xuejun Chen, Lea M Burke, Feng Zhou, Fred Zheng, Pankit Vachhani
Journal: Blood
Blood (2024) 144 (Supplement 1): 658.
https://doi.org/10.1182/blood-2024-200925
Published: 2024
Journal Articles

Evaluation of Itacitinib Impact on TNFα Levels Following Immune Effector Cell (IEC) Therapy Using PKPD Modeling and Simulation Approaches

Olga Ivanova, Michael Pratta, Ivan Azarov, Kirill Zhudenkov, Yuri Kosinsky, Kirill Peskov, Xuejun Chen, Jennifer Sheng
Journal: Blood
Blood (2024) 144 (Supplement 1): 7129.
https://doi.org/10.1182/blood-2024-199649
Published: 2024
Journal Articles

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Justin M. Watts, Alessandro M. Vannucchi, Anthony M. Hunter, Brandon McMahon, Srinivas K. Tantravahi, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Emma Searle, Brandi N. Reeves, Prithviraj Bose, Rosa Ayala, Anna B. Halpern, Xuejun Chen, Lea M Burke, Feng Zhou, Fred Zheng, Pankit Vachhani
Journal: Blood
Blood (2023) 142 (Supplement 1): 750.
https://doi.org/10.1182/blood-2023-179428
Published: 2023
Journal Articles

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Justin Watts, Anthony M. Hunter, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Brandi Reeves, Alessandro M. Vannucchi, Xuejun Chen, Francis Seguy, Feng Zhou, Fred Zheng, Pankit Vachhani
Journal: Blood
Blood (2022) 140 (Supplement 1): 9696–9697.
https://doi.org/10.1182/blood-2022-169740
Published: 2022
Journal Articles

Population Pharmacokinetics of Ruxolitinib in Patients with aGVHD Who Had an Inadequate Response to Corticosteroids

Xuejun Chen, Xiang Liu, Phillip Wang, Swamy Yeleswaram, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4534.
https://doi.org/10.1182/blood-2019-124027
Published: 2019
Journal Articles

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William J. Edenfield, Paolo Caimi, Martin Gutierrez, Luke Akard, Carolina Escobar, Justin Call, Daniel Persky, Swaminathan Iyer, Douglas J. DeMarini, Li Zhou, Xuejun Chen, Fitzroy Dawkins, Tycel J. Phillips
Journal: Blood
Blood (2019) 133 (16): 1742–1752.
https://doi.org/10.1182/blood-2018-08-867499
Published: 2019
Includes: Supplemental data
Journal Articles

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Clinical Trials & Observations
Tycel J. Phillips, Andres Forero-Torres, Taimur Sher, Catherine S. Diefenbach, Patrick Johnston, Moshe Talpaz, Jennifer Pulini, Li Zhou, Peggy Scherle, Xuejun Chen, Paul M. Barr
Journal: Blood
Blood (2018) 132 (3): 293–306.
https://doi.org/10.1182/blood-2017-10-812701
Published: 2018
Includes: Supplemental data
Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD
Journal: Blood
Blood (2016) 128 (22): 4195.
https://doi.org/10.1182/blood.V128.22.4195.4195
Published: 2016